| abstract |
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER INCLUDING TRYPSINOGEN AND/OR CHYMOTRIPSINOGEN AND ACTIVE AGENT SELECTED FROM SELENIUM COMPOUND, VANILLOID COMPOUND AND CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and their use in the treatment of cancer. Pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being able to provide a multifunctional approach to the treatment of cancer. Pharmaceutical compositions are also directed to compositions comprising a first and second protease proenzyme capable of activation on or near a tumor cell surface to enhance cell-to-cell adhesion of tumor cells, effecting proteolysis of tumor cells, or inducing apoptosis, differentiation, or immunorecognition of tumor cells, where the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. Pharmaceutical compositions are also directed to compositions comprising a first and second active agents, ca. |